VANCOUVER, British Columbia, May 21, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (CSE: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company revolutionizing the delivery of healthcare to patients, is proud to announce that one of their clinics’ doctors, Tahmeena Ali received the BC Family Physician of the Year Award from the BC College of Family Physicians.
The BC College of Family Physicians is an organization representing over 6000 physicians across the province. The award recognizes a family doctor who provides exemplary care to patients and takes part in activities that contribute to excellence in family medicine.Dr. Ali practices full-service family medicine at one of the CloudMD clinics. She was an early adopter to incorporate telemedicine into her practice and greatly assisted with the workflow and development of CloudMD’s patient focused model of care. CloudMD’s hybrid model incorporates virtual care to supplement in person visits. Along with colleagues and representatives from the Surrey School District and the Ministry for Child and Family Development, she created the School Triage Team which provides a much-needed interface between mental health professionals and school teachers. In addition, Dr. Ali is the current chair of the Division of Family Practice of White Rock/South Surrey and previously headed an Acquired Brain Injury unit where she further recognized the power of providing complex psychiatry patients with optimal and supportive follow-up upon discharge.Dr. Ali is enthusiastic about CloudMD’s technology enabled mental health initiative. The innovative solution focuses on providing app enabled mental health counselling to support patients. Through private and secure online video, people can easily access and book sessions with experienced professionals when and where they need it. The Company also focuses on providing access to mental health to underserved and under privileged communities, which due to geography and the scarcity of mental health professionals, have previously been overlooked.“I am honoured to be awarded BC’s Family Physician of the Year award, and I am proud of all my peers for our continued efforts during these trying times,” said Dr. Ali. “CloudMD’s technology supports the most important tenet in family practice: longitudinal care. Providing virtual care allows me to care for my patients from Lillooet to Langley and minimizes the barriers for my patients to obtain care from their family physician—the provider who knows them best. That relationship makes it easier for patients to open up about challenging topics, like mental health, even when we talk about it over an app.”Dr. Essam Hamza, CEO of CloudMD commented, “Congratulations to Dr. Ali for receiving this prestigious award. Her hard work, innovation and dedication to BC’s healthcare sector makes her a perfect candidate for the award. We continue to be impressed with, and inspired by, the innovative work she’s doing. It’s an honour to work with her and we are proud she is part of our CloudMD team.”CloudMD also announces that it will issue an aggregate of 150,000 common shares (the “Shares”) of the Company to an insider, in consideration for services rendered. Pursuant to the terms of a services agreement (the “Services Agreement”), a total of 150,000 Shares will be issued to Mark Kohler in consideration for advisory services provided to the Company in his capacity as Director and Chairman. The common shares are being issued as a shares for services transaction, at a deemed price of $0.75 per common share. The disinterested directors of the Company have approved the Services Agreement with the insider. The Shares issued are subject to escrow and will be released on a monthly basis and all securities issued pursuant to the Services Agreement will be subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws. The Company confirms that a new Control Person has not been created.The insider shares for services transaction is exempt from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 (“MI 61-101”) by virtue of the exemptions contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in that the fair market value of the consideration for the securities of the Company to be issued to the insiders does not exceed 25% of its market capitalization.About CloudMD Software & ServicesCloudMD is digitizing the delivery of healthcare by providing patients access to all points of their care from their phone, tablet or desktop computer. The Company offers SAAS based health technology solutions to medical clinics across Canada and has developed proprietary technology that delivers quality healthcare through the combination of connected primary care clinics, telemedicine, and artificial intelligence (AI). CloudMD currently provides service to a combined ecosystem of 376 clinics, over 3000 licensed practitioners and almost 3 million patient charts across its servers.ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD”
Chief Executive OfficerFOR ADDITIONAL INFORMATION CONTACT:CloudMD Software & Services Inc.
Email: firstname.lastname@example.orgForward Looking StatementsThis news release contains forward-looking statements that are based on CloudMD’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans. Although CloudMD believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and CloudMD undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Tempus Launches COVID-19-Specific Clinical and Research Initiatives for Oncology
CHICAGO, May 30, 2020 (GLOBE NEWSWIRE) — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a series of offerings designed to both advance vital research and support physicians in treating cancer patients, despite the challenges of the COVID-19 pandemic. Tempus is equipping physicians with the tools they need to treat high-risk patients while limiting their exposure to the virus, with mobile phlebotomy services, on-demand virtual case reviews, and COVID-19 PCR diagnostic testing for cancer patients.
“Cancer continues to be among the leading causes of death worldwide, and now more than ever, it is critical that cancer patients continue to receive the care and treatment they need for survival despite the pandemic,” said Eric Lefkofsky, Founder and CEO. “In the last few months, we’ve quickly mobilized to create offerings that ease the burden on physicians treating cancer patients amidst the threat of COVID-19, through a series of services and tests that are badly needed to ensure therapies aren’t disrupted.”COVID-19 PCR Diagnostic Testing
Earlier this month, Tempus launched a diagnostic polymerase chain reaction (PCR) test for COVID-19. Tempus’ CAP-accredited/CLIA-certified labs in Chicago and Atlanta are supporting the acceleration of testing in the U.S., and expect to test approximately 12,000 patients daily across both labs, with the ability to scale further if needed. Tempus makes it seamless for physicians to test their patients for the virus, providing results within 24-48 hours at no cost to the patient as Tempus bills insurance directly. Mobile Phlebotomy
Tempus now offers mobile phlebotomy services, which are available to patients who require a blood draw but are too sick or unable to travel to the clinic, or do not have access to an in-office phlebotomist or draw site. Experts are able to perform blood draws in patients’ homes for any Tempus test in which a blood sample is required, at no added cost.Virtual Case Reviews
Tempus’ on-demand virtual case review system provides clinical support to physicians and care teams in a timely manner when an in-person meeting isn’t possible. Tempus’ Medical Affairs team is available to answer patient report questions in real-time in a secure portal. In addition, Tempus now offers a variety of tele-health support services specific to COVID-19 if needed.Research Collaboration
Tempus has launched a large research collaboration to structure data for up to 50,000 COVID-19 positive patients. As part of the IRB approved study, Tempus is partnering with providers to collect data on COVID-19 patients, which Tempus is structuring and de-identifying without cost. In addition, Tempus expects to perform full transcriptomic profiling of approximately 10,000 patients within the cohort. All data will be shared with all participating institutions without restriction. About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.Erin Carron
Tempus’ TIME Trial™ Program Reaches Critical Scale and Operational Milestones
CHICAGO, May 29, 2020 (GLOBE NEWSWIRE) — Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation (TIME) Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials. To date, Tempus has signed up over 50 provider networks, over 30 unique biomarker trials, and has rapidly opened sites onto trials in an average of 10 days. Through the TIME Trial™ Program, Tempus is bringing the very best clinical trials to communities across the country, giving thousands of patients access to novel therapeutics.
“We have experience with clinical trial rapid deployment models, however Tempus provides an unparalleled level of commitment and support in aligning all involved parties and streamlining the process, especially given the challenges of the COVID-19 pandemic,” said Dr. Julio Peguero, Director of Research of Oncology Consultants. “We ultimately met our target goal of activating this trial in just two weeks, and hope to do the same for future patients.”Last spring, Tempus launched the TIME Trial™ Program in an effort to increase clinical trial participation by using real-time clinical and molecular data to match patients to trials, and then rapidly open pre-qualified sites once a patient has been identified. Since then, Tempus has built its TIME Trial™ Network, inclusive of some of the country’s top community hospitals and academic medical centers, totaling over 50 research sites and 2,500 oncologists.As of today, the program has 30 pharma-sponsored clinical trials, covering dozens of unique, actionable biomarkers across both solid and hematological malignancies. Every week, Tempus screens thousands of new patients against the criteria of the ultra-rare trials in the TIME Trial™ Network. Thus far, Tempus has matched nearly 1,000 patients to the trials in its portfolio and averaged just under 10 days from patient screened to site activated.“Cutting-edge cancer therapies increasingly target narrower populations of patients, and the clinical trials that study these therapies require equally specific patient populations,” said Amy Franzen, Vice President of Operations and Program Lead. “Tempus is able to use its advanced technology, access to real-time data, and strong operations to get the right patients access to the right therapies, closer to home.”Tempus screens patients from sites in the TIME Trial™ Network against applicable inclusion/exclusion criteria utilizing genomic sequencing data, matched with the patients’ clinical data. Then, Tempus applies its computational algorithm to provide rapid, comprehensive matches to applicable trials that can be brought to the patient. Once a patient has been screened and matched, Tempus provides the patient’s physician with a report that ranks relevant trials. If the physician expresses interest in enrolling his or her patient in a trial, the Site and Sponsor leverage a standard contract, standard rate card, and a central IRB to rapidly open the clinical trial and enroll the patient into the study in under two weeks.For the same reason that precision medicine is now possible due to technological advances such as cost effective genomic sequencing at scale, the maturing of artificial intelligence, and the evolution of cloud technology, it is now possible to run clinical trials more efficiently and based on real-time data. Tempus is increasing the speed of clinical trials and reaching into community settings, where the majority of cancer patients are treated today.About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Completely Online Summer Math Camps Offered to Meet Strong Demand from Parents During COVID-19
San Diego, May 29, 2020 (GLOBE NEWSWIRE) — Parents looking for a summer camp this year may find that there are limited options due to COVID-19 social distancing guidelines. Art of Problem Solving (AoPS), a leader in math education that has prepared hundreds of thousands of students for some of the most prestigious universities, has transformed its Summer Camp activities online to create a collaborative learning and social space for children in third grade through high school. The Summer Camp activities help students develop problem solving skills through group activities in math and related subjects.Though this is the fourth year that Art of Problem Solving has offered a Summer Camp, this is the first time the organization is offering the camp experience completely online. Activities include learning how to develop cryptographic skills to protect internet security, to a class that integrates math learning as part of a poetry project that concludes with a Poetry Slam. The two-week and four-week sessions start in June and last through the summer.“As a result of the COVID-19 pandemic, many parents are seeking a summer camp experience for their children that conforms to social distancing norms while encouraging learning and collaboration,” said Richard Rusczyk, the founder of Art of Problem Solving, which has offered classes since 2003. “At Art of Problem Solving, we quickly adapted our on-campus Summer Camp experience with our online academic models. Our first-ever online Summer Camp is designed to encourage students to develop problem solving skills in a personalized and collaborative group environment.”The COVID-19 pandemic has created wider public awareness of the relevancy of math and statistics in everyday life. Rusczyk said his organization has seen that interest reflected in demand from more parents and children who see math skills as increasingly important. Also, in response to COVID-19, the company offered for a limited time a free trial to its Beast Academy program that integrates comic-style “beast” characters and exercises, puzzles and games.The Art of Problem Solving began in 1993 with a pair of textbooks for middle and high school math contest participants. Ten years later, Art of Problem Solving launched a website with an online school and full math curriculum designed for high-performing math learners. Every member of the 2015, 2016, 2018, and 2019 U.S. International Math Olympiad teams―each of which took first place in the competition―are Art of Problem Solving alumni who collectively participated in more than 110 Art of Problem Solving Online courses. The Art of Problem Solving is an ACS WASC Accredited School that offers programs online and, prior to COVID-19, at its nationwide campus locations. The organization also works with school districts to integrate their offerings as part of school math lessons.Looking beyond the immediate pandemic, problem solving skills are considered to be essential to the nation’s future workforce. As professions shift toward greater use of automation and artificial intelligence, there is expected to be an increased demand for people who have the ability to identify creative solutions and manage these developments. Critical thinking and problem solving is a top skill identified by National Association of Colleges and Employers.About Art of Problem SolvingArt of Problem Solving has successfully trained hundreds of thousands of motivated students in preparation for success at top-tier colleges and careers. Through rigorous, high-quality K-12 math curriculum, online classes and learning centers, Art of Problem Solving trains today’s brightest minds to solve tomorrow’s challenges. For additional information, visit www.artofproblemsolving.com.Jaclyn Walian
Latest News11 months ago
Bleckwen Raises $10m and Appoints David Christie as CEO
Artificial Intelligence1 year ago
Kneron Debuts Edge AI Chip, Bringing AI to Devices Everywhere
Artificial Intelligence1 year ago
Chartis Research Names FICO a Category Leader in AI for Financial Services
Artificial Intelligence12 months ago
LogRhythm Scores the Singapore Business Review Technology Excellence Award 2019 for Cyber Security – Computer Software
Artificial Intelligence1 year ago
CredoLab extends smartphone-based scoring to insurers
Artificial Intelligence1 year ago
Tuya Exhibiting Products from its Global Clients that are “Powered by Tuya”
Artificial Intelligence12 months ago
Chengdu Tianfu Software Park Reflects the Vitality of IP Innovation
Artificial Intelligence8 months ago
Mogo announces a digital lending pilot with goeasy Ltd.